跳至主要内容
临床试验/NCT01617122
NCT01617122Unknown不适用

To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency

University of South Florida2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 1995年10月最近更新:
适应症

试验速览

阶段
不适用
入组人数
200
试验地点
2
主要终点
Evidence of capacity of switch from IgM to IgG.

研究概览

简要总结

This protocol is designed to ascertain whether the bacteriophage 0X174 neoantigen is safe and effective as an antigen used in the evaluation of primary and secondary immune responses. Bacteriophage 0X174 is given intravenously 2 billion PFU/Kg of body weight; small blood specimens of 3-5 ml (about 1 teaspoon) are collected after 15 minutes, 7 days, 14 days, and 28 days. Blood is collected at intervals following the administration of the bacteriophage and the number of phage/ml is determined by the agar overlay method using suspension of E. coli C and serially diluted patient's serum. Phage-specific IgG and IgM are measured by neutralization assay. Capacity of switch from IgM to IgG is determined.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
2 Years 至 85 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • subject/parent or guardian willing to sign consent and adhere to study schedule
  • known or suspected primary immune deficiency

排除标准

  • breastfeeding
  • unwilling to sign consent or adhere to study schedule
  • < 2 yrs of age or > 85 yrs of age
  • previous reaction to vaccine

结局指标

主要结局

Evidence of capacity of switch from IgM to IgG.

时间窗: 12 weeks

Blood samples are obtained after each immunizition of Bacteriophage.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验